<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04373967</url>
  </required_header>
  <id_info>
    <org_study_id>TQF2451-III-01</org_study_id>
    <nct_id>NCT04373967</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes</brief_title>
  <official_title>A Phase III,Randomized,Parallel,Open-label,Multicenter Trial to Compare the Efficacy and Safety of Liraglutide and Victoza® in Patients With Type 2 Diabetes Inadequately Controlled by Oral Metformin Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liraglutide injection is a glucagon-like peptide-1 (GLP-1) analogue that activates the cyclic
      adenosine monophosphate (cAMP) and mitogen-activated protein kinase (MAPK) pathway by binding
      to the GLP-1 receptor (GLP-1R),thus,it has physiological effects such as glucose-dependent
      insulin synthesis and secretion, inhibition of β-cell apoptosis, promotion of β-cell
      proliferation and regeneration, inhibition of glucagon secretion, reduction of food intake,
      delay of gastric emptying, enhancement of glucose utilization in peripheral tissues and
      reduction of glycogen output. Liraglutide injection,developed and marketed as Victoza® by
      Novo Nordisk,is indicated for the treatment of patients with type 2 diabetes and was approved
      by the U.S. Food and Drug Administration in 2010.This 26-week trial compares the effectivity
      on glycaemic control,safety and immunogenicity of liraglutide injection and Victoza® in
      patients with type 2 diabetes inadequately controlled by oral metformin alone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 29, 2020</start_date>
  <completion_date type="Anticipated">December 2, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>glycated hemoglobin (HbA1c)</measure>
    <time_frame>week 0,week 26</time_frame>
    <description>Changes in glycated hemoglobin (HbA1c) relative to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>week 0,week 26</time_frame>
    <description>Changes in body weight relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of achieving HbA1c target (&lt;7.0% or ≤6.5%)</measure>
    <time_frame>week 0,week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c change from baseline</measure>
    <time_frame>week 0,week 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting venous blood glucose (FPG).</measure>
    <time_frame>week 0,week 14,week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in 2h-Postprandial Blood Glucose(2h-PBG).</measure>
    <time_frame>week 0,week 14,week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting insulin.</measure>
    <time_frame>week 0,week 14,week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting C peptide.</measure>
    <time_frame>week 0,week 14,week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in systolic blood pressure.</measure>
    <time_frame>week 0,week 14,week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in diastolic blood pressure.</measure>
    <time_frame>week 0,week 14,week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events and serious adverse events during exposure to trail product.</measure>
    <time_frame>week 0-26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-emergent severe or blood glucose-confirmed symptomatic hypoglycaemic episodes during exposure to trail product.</measure>
    <time_frame>week 0-26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive rate of liraglutide anti-drug antibody(ADA).</measure>
    <time_frame>week 0-26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with clinically significant change from baseline in vital signs.</measure>
    <time_frame>week 0-26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with clinically significant change from baseline in laboratory parameters.</measure>
    <time_frame>week 0-26</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">424</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>TQZ2451+metformin hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQZ2451 injection (0.6mg qd from baseline to week 1;1.2mg qd during week 2;1.8mg qd from week 3 to week 26) + metformin hydrochloride sustained-release tablets (1500-2000mg qd)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Victoza®+metformin hydrochloride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Victoza® (0.6mg qd from baseline to week 1;1.2mg qd during week 2;1.8mg qd from week 3 to week 26) + metformin hydrochloride sustained-release tablets (1500-2000mg qd)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Victoza®.</intervention_name>
    <description>Patients will receive Victoza®. Both products will be provided as pen-injector.</description>
    <arm_group_label>Victoza®+metformin hydrochloride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Hydrochloride</intervention_name>
    <description>Patients who were receiving metformin prior to study will continue to receive it during the study.</description>
    <arm_group_label>TQZ2451+metformin hydrochloride</arm_group_label>
    <arm_group_label>Victoza®+metformin hydrochloride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQZ2451</intervention_name>
    <description>Patients will receive TQZ2451.Both products will be provided as pen-injector.</description>
    <arm_group_label>TQZ2451+metformin hydrochloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed as type 2 diabetes.

          -  Stably daily dose of metformin alone[between the dose of 1500mg and 2000mg inclusive]
             for at least 12 weeks prior to day of screening .

          -  HbA1c(glycosylated haemoglobin) of 7-11%(both inclusive).

          -  Body mass index (BMI) of 18.5-45 kg/m2(both inclusive).

          -  The patient must give informed consent to the study before the trial and voluntarily
             sign the informed consent form.

          -  The patient can communicate well with the researcher and complete the study in
             accordance with the research regulations.

        Exclusion Criteria:

          -  Diagnosed as type 1 or other types of diabetes.

          -  Treatment with glucagon-like peptide-1 (GLP-1) receptor agonist, dipeptidyl
             peptidase-4 (DPP-4) inhibitor and insulin treatment within 3 months before
             screening.[short term (cumulative use ≤7 days) insulin therapy due to intermittent
             disease is excluded]

          -  Treatment with systemic glucocorticoid therapy within 3 months before
             screening[topical medication or inhaled product is excluded] .

          -  Treatment with Chinese medicine preparations having hypoglycemic effects within 1
             month before screening.

          -  Patients with recurrent severe or unconscious hypoglycemia within 3 months before
             screening.

          -  Patients with acute metabolic complications (ketoacidosis, lactic acidosis or
             hypertonic coma, etc.) within 6 months before screening.

          -  History of chronic pancreatitis or idiopathic acute pancreatitis, or suffering from
             acute or chronic pancreatitis during screening, or blood amylase ≥ 3 times of the
             upper limit of normal value, or triglycerides ≥ 8.0 mmol / L.

          -  Fasting blood-glucose(FBG)≥15.0 mmol / L on the day of screening.

          -  Personal or family history of medullary thyroid carcinoma (MTC) or type 2 multiple
             endocrine adenoma (MEN2).

          -  Patients with obvious liver and kidney dysfunction (alanine aminotransferase (ALT)&gt;
             2.5 × upper normal value (ULN), aspartate aminotransferase (AST)&gt; 2.5 ULN, glomerular
             filtration rate &lt;60 Milliliter(mL) / min / 1.73m2

          -  Hemoglobin &lt;lower limit of normal value.

          -  Hyperthyroidism is being treated or the dosage of hypothyroidism is not stable within
             6 months.

          -  Uncontrolled or poorly treated hypertension (systolic blood pressure ≥160 mmHg or
             diastolic blood pressure ≥100 mmHg).

          -  Patients with decompensated heart failure (NYHA grades III and IV), unstable angina,
             stroke or transient ischemic attack, myocardial infarction, severe arrhythmia, cardiac
             surgery or vascular reconstruction performed (including coronary artery bypass
             grafting or percutaneous coronary intervention) within 6 months before screening.

          -  Proliferative retinopathy or macular disease (macular edema) that requires urgent
             treatment.

          -  Malignant tumors (except basal cell carcinoma or phosphorous cell skin cancer)
             diagnosed within the past 5 years.

          -  Patients with severe chronic gastrointestinal disease (such as active peptic ulcer)
             and severe infections.

          -  People who are allergic to any of the ingredients in metformin, liraglutide injection
             and Victoza®.

          -  Participated in any other clinical trials within 3 months before screening.

          -  Pregnant women, lactating women and women of reproductive age who did not take
             appropriate contraception (sterilization, intrauterine devices, oral contraceptives or
             barrier contraception) during the trial.

          -  History of psychotropic substance abuse, alcohol abuse or drug addiction.

          -  Patients judged as unsuitable participants of the trial by researchers or with poor
             compliance.

          -  According to the investigators' judgment, there are seriously concomitant diseases
             endanger the safety of the patient or prevent the patient from completing the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dalong Zhu, doctor</last_name>
    <phone>025-68182432</phone>
    <email>zhudalong@nju.edc.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Second Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tianrong Pan, Master</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second People's Hospital of Heifei</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jun Ye, Bachelor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ma'anshan People's Hospital</name>
      <address>
        <city>Ma'anshan</city>
        <state>Anhui</state>
        <zip>243000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weihong Chen, Bachelor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yijishan Hospital of Wannan Medical College</name>
      <address>
        <city>Wuhu</city>
        <state>Anhui</state>
        <zip>241000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jialin Gao, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rong Li, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ninth People's Hospital of Chongqing</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xingrong Tan, Master</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Long, Master</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Guangdong Medical University</name>
      <address>
        <city>Zhanjiang</city>
        <state>Guangdong</state>
        <zip>524000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fuzhen Liu, Master</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liuzhou People's Hospital</name>
      <address>
        <city>Liuzhou</city>
        <state>Guangxi</state>
        <zip>545000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yulan Li, Master</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Nanning</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuanyuan Lin, Master</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Guizhou Medical University</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <zip>550000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Hu, Master</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yukun Li, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Fourth Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhifeng Cheng, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guoqing Ma, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Henan University of Science and Technology</name>
      <address>
        <city>Luoyang</city>
        <state>Henan</state>
        <zip>471000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liujun Fu, Master</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinxiang Central Hospital</name>
      <address>
        <city>Xinxiang</city>
        <state>Henan</state>
        <zip>453000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiuqin Geng, Master</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Zhengzhou</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qijuan Dong, Bachelor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third People's Hospital of Hebei</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juping Hu, Bachelor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second People's Hospital of Lianyungang</name>
      <address>
        <city>Lianyungang</city>
        <state>Jiangsu</state>
        <zip>222000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yunming Gao, Bachelor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dalong Zhu, Doctor</last_name>
      <phone>025-68182432</phone>
      <email>zhudalong@nju.edc.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanjing Jiangning Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kun Wang, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xuzhou Third People's Hospital</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <zip>221000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunrong Xu, Master</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanchang First Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ling Hu, Bachelor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Changchun University of Chinese Medicine</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiuge Wang, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jilin Province FAW General Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chengwei Song, Master</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanjun Wang, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meihekou Central Hospital</name>
      <address>
        <city>Tonghua</city>
        <state>Jilin</state>
        <zip>134000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongwei Jin, Master</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dalian Municipal Central Hospital Affiliated of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liangning</state>
        <zip>116000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhengnan Gao, Master</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Ningxia Hui Autonomous Region</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <zip>750000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongmei Li, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jinan Central Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaolin Dong, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weifang Traditional Chinese Hospital</name>
      <address>
        <city>Weifang</city>
        <state>Shandong</state>
        <zip>261000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jie Zhang, Master</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Pudong Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dongxiang Xu, Bachelor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Changzhi People's Hospital</name>
      <address>
        <city>Changzhi</city>
        <state>Shanxi</state>
        <zip>046000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenhua Zhao, Master</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peace Hospital Affiliated to Changzhi Medical College</name>
      <address>
        <city>Changzhi</city>
        <state>Shanxi</state>
        <zip>046000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huwei Shen, Bachelor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jincheng General Hospital</name>
      <address>
        <city>Jincheng</city>
        <state>Shanxi</state>
        <zip>048000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lili Zhang, Master</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xing Li, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanxi Provincial People's Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanlan Yang, Bachelor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi'an Jiaotong Univesity</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hui Guo, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of The Fourth Military Medical University</name>
      <address>
        <city>Xian</city>
        <state>Shanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaomiao Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital)</name>
      <address>
        <city>Xian</city>
        <state>Shanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Xu, Master</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yuncheng Central Hospital</name>
      <address>
        <city>Yuncheng</city>
        <state>Shanxi</state>
        <zip>044000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Li, Bachelor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>General Hospital of Tianjin Medical University</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Liu, Master</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin First Central Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xia Jiang, Bachelor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Kunming Medical University</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yushan Xu, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Provincial People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaohong Wu, Doctor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taizhou First People's Hospital</name>
      <address>
        <city>Taizhou</city>
        <state>Zhejiang</state>
        <zip>318000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lijun Wang, Bachelor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 28, 2020</study_first_submitted>
  <study_first_submitted_qc>May 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2020</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

